- Home
- IMUX vs ANL Comparison
IMUX vs ANL Comparison
Compare IMUX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- ANL
- Stock Information
- Founded
- IMUX 2016
- ANL 2004
- Country
- IMUX United States
- ANL Cayman Islands
- Employees
- IMUX N/A
- ANL N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- IMUX Health Care
- ANL
- Exchange
- IMUX Nasdaq
- ANL Nasdaq
- Market Cap
- IMUX 86.3M
- ANL 79.0M
- IPO Year
- IMUX N/A
- ANL 2023
- Fundamental
- Price
- IMUX $1.27
- ANL $2.25
- Analyst Decision
- IMUX Strong Buy
- ANL Strong Buy
- Analyst Count
- IMUX 6
- ANL 2
- Target Price
- IMUX $12.67
- ANL $9.00
- AVG Volume (30 Days)
- IMUX 795.3K
- ANL 5.8K
- Earning Date
- IMUX 03-04-2025
- ANL 03-04-2025
- Dividend Yield
- IMUX N/A
- ANL N/A
- EPS Growth
- IMUX N/A
- ANL N/A
- EPS
- IMUX N/A
- ANL N/A
- Revenue
- IMUX N/A
- ANL $5,000,000.00
- Revenue This Year
- IMUX N/A
- ANL N/A
- Revenue Next Year
- IMUX N/A
- ANL N/A
- P/E Ratio
- IMUX N/A
- ANL N/A
- Revenue Growth
- IMUX N/A
- ANL N/A
- 52 Week Low
- IMUX $0.92
- ANL $1.85
- 52 Week High
- IMUX $2.11
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- IMUX 72.48
- ANL 57.33
- Support Level
- IMUX $0.92
- ANL $2.00
- Resistance Level
- IMUX $1.15
- ANL $2.15
- Average True Range (ATR)
- IMUX 0.07
- ANL 0.11
- MACD
- IMUX 0.03
- ANL 0.03
- Stochastic Oscillator
- IMUX 74.47
- ANL 59.52
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.